ROIV · Roivant Sciences Ltd.
$34.91
+0.54% last session
End-of-day data · updated 2026-07-24
Market cap
$25B
Enterprise value
$22B
Trailing P/E
—
Forward P/E
-22.5
Dividend yield
—
Beta
1.11
Avg volume
6M
Employees
1K
2D change
0.54%
5D change
1.71%
10D change
0.54%
30D change
3.20%
60D change
17.16%
MTD change
0.20%
YTD change
61.75%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ROIV
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-26
Latest call per bank · past 12 months
Citigroup
Buy$42.00
+20.3% vs priceGoldman Sachs
Buy$33.00
-5.5% vs priceJefferies
Buy$20.00
-42.7% vs priceJP Morgan
Overweight$20.00
-42.7% vs priceBank of America
Neutral$16.50
-52.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-26 | Guggenheim | Maintains | Buy | $30.00 → $36.00 |
| 2026-05-21 | Citigroup | Maintains | Buy | $35.00 → $42.00 |
| 2026-05-21 | TD Cowen | Maintains | Buy | $38.00 → $41.00 |
| 2026-05-21 | HC Wainwright & Co. | Reiterates | Buy | $34.00 |
| 2026-04-16 | Piper Sandler | Maintains | Overweight | $22.00 → $40.00 |
| 2026-03-04 | HC Wainwright & Co. | Maintains | Buy | $33.00 → $34.00 |
| 2026-02-10 | Citigroup | Maintains | Buy | $26.00 → $35.00 |
| 2026-02-10 | HC Wainwright & Co. | Maintains | Buy | $26.00 → $33.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 59 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 9.9% above the 50-day MA ($31.95).
- Price vs 200-day MA: Trading 35.6% above the 200-day MA ($25.88).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.25) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($36.81).
ROIV Price Chart
Loading chart for ROIV…
Fundamentals
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$120B 4.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$68B -15.3% YTD
ARGX
argenx SE
$58B 10.0% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -32.4% YTD
ONC
BeOne Medicines Ltd.
$34B 7.6% YTD
RPRX
Royalty Pharma plc
$34B 54.2% YTD
INSM
Insmed Incorporated
$23B -38.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.